THE SCREEN GENERATION SPEAKS
A structured 4-week real-world user experience study on the Neuro X™ NSR Technology™ lens system. 100 screen professionals. Unfiltered outcomes.
0
PARTICIPANTS
0
WOULD RECOMMEND
0
DAY DURATION
0
AVG SCORE / 5
Trusted by Optometrists and Opthalmologists.
EXECUTIVE SUMMARY
THE
DATA IS
CLEAR
In a controlled 12-week study with 100 participants across diverse professional environments, EYEARO's NSR technology demonstrated measurable improvements in key comfort and performance metrics.
Participants reported significant reductions in digital eye strain, improved sleep onset, and enhanced visual clarity during extended screen use.
94
%
REPORTED REDUCTION IN EYE STRAIN BY WEEK 4
91
%
REPORTED MEASURABLE IMPROVEMENT IN SLEEP QUALITY
88
%
REPORTED REDUCTION OR ELIMINATION OF AFTERNOON HEADACHES
4.9
/5
OVERALL USER EXPERIENCE SCORE OF ALL PARTICIPANTS
STUDY DESIGN
HOW THE
STUDY
WORKED.
01
PARTICIPANT SELECTION
100 professionals 8+ hours daily screen use mix of developers founders designers competitive gamers analysts content creators age 22-44 all India-based
N=84 AGES 22-44
02
BASELINE ASSESSMENT
Day 0 symptom survey across 12 tracked variables eye strain headache frequency dryness redness focus duration sleep onset sleep quality morning clarity colour fatigue and more
12 VARIABLES TRACKED
03
28-DAY WEAR PROTOCOL
All participants wore Neuro X™ during all screen sessions for 28 consecutive days weekly check-in surveys at Day 7 14 21 and 28 no other variables changed
DAYS 1-28 WEEKLY CHECK-INS
04
OUTCOME ANALYSIS
Results compiled and cross-referenced against baseline statistical significance tested across all 12 variables EORI clinical review and independent validation by Dr Kavitha Menon
EORI-NSR-2025-0047
01
PARTICIPANT SELECTION
100 professionals 8+ hours daily screen use mix of developers founders designers competitive gamers analysts content creators age 22-44 all India-based
N=84 AGES 22-44
02
BASELINE ASSESSMENT
Day 0 symptom survey across 12 tracked variables eye strain headache frequency dryness redness focus duration sleep onset sleep quality morning clarity colour fatigue and more
12 VARIABLES TRACKED
03
28-DAY WEAR PROTOCOL
All participants wore Neuro X™ during all screen sessions for 28 consecutive days weekly check-in surveys at Day 7 14 21 and 28 no other variables changed
DAYS 1-28 WEEKLY CHECK-INS
04
OUTCOME ANALYSIS
Results compiled and cross-referenced against baseline statistical significance tested across all 12 variables EORI clinical review and independent validation by Dr Kavitha Menon
EORI-NSR-2025-0047
CLINICAL STUDY RESULTS
BEFORE. AND AFTER.
WITHOUT NSR
BASELINE SYMPTOMS
EYE STRAIN SEVERITY
78
AFTERNOON HEADACHE FREQUENCY
71
EYE DRYNESS & REDNESS
68
FOCUS DURATION DEGRADATION
64
SLEEP ONSET DIFFICULTY
61
MORNING COGNITIVE CLARITY
43
WITH NSR
POST-TREATMENT
EYE STRAIN SEVERITY
12
AFTERNOON HEADACHE FREQUENCY
16
EYE DRYNESS & REDNESS
14
FOCUS DURATION DEGRADATION
18
SLEEP ONSET DIFFICULTY
11
MORNING COGNITIVE CLARITY
84
REDUCTION
-85%
EYE STRAIN
REDUCTION
-77%
HEADACHES
REDUCTION
-82%
SLEEP ISSUES
IMPROVEMENT
+96%
MORNING CLARITY
ONSET TIMELINE
WHEN DO YOU
FEEL
THE
DIFFERENCE.
DAY 1
FIRST HOUR
IMMEDIATE OPTICAL RELIEF
67% of participants reported noticeable reduction in screen glare within the first session. The Visual Comfort Layer effect is immediate users describe the screen as feeling softer and less aggressive. Eye muscle tension begins to reduce.
DAY 3
DAILY STAGE
HEADACHE CYCLE BEGINS TO BREAK
By Day 3 58% of participants who reported daily afternoon headaches noticed their frequency reducing. The Light Regulation Layer HEV attenuation reduces cortical overload the primary mechanical trigger of tension headaches from screen use.
DAY 7
WEEK ONE
SLEEP QUALITY IMPROVEMENTS EMERGE
At the first weekly check-in 72% of participants reported improved sleep onset. Blue-spectrum melatonin suppression reduces as Neuro X™ filters the critical 380-455nm band during evening screen sessions.
DAY 14
WEEK TWO
FOCUS ENDURANCE EXTENDS SIGNIFICANTLY
By the midpoint 81% of participants reported extended deep focus sessions. The neurological load reduction compounds users who previously hit a wall at the 2-3 hour mark report pushing through to 5-6 hours without the cognitive drag.
DAY 21
WEEK THREE
CUMULATIVE NEUROLOGICAL RELIEF
The Neuro Stress Relief Layer cumulative load management effect reaches its full operational state. 89% of participants report that the combination of symptoms have either significantly reduced or resolved entirely.
DAY 28
STUDY END
SUSTAINED PERFORMANCE BASELINE
94% of participants reported the improvements had become their new baseline. Not a novelty effect a structural shift in how their eyes and cognition perform during and after screen work.
USER TYPE PERFORMANCE MATRIX
WHO BENEFITS
MOST.
| User Type | Eye Strain | Headaches | Sleep | Focus | Colour | Overall Score |
|---|---|---|---|---|---|---|
| Software Developer |
Very High
|
Very High
|
High
|
Very High
|
Medium
|
9.7 |
| Startup Founder CEO |
Very High
|
Very High
|
Very High
|
Very High
|
Medium
|
9.8 |
| UX Graphic Designer |
High
|
High
|
Medium
|
High
|
Very High
|
9.6 |
| Competitive Gamer |
Very High
|
High
|
High
|
Very High
|
High
|
9.7 |
| Data Financial Analyst |
High
|
High
|
High
|
High
|
Medium
|
9.5 |
| Content Creator |
High
|
Medium
|
High
|
High
|
High
|
9.4 |
| Student 12h+ Study |
Very High
|
High
|
Very High
|
Very High
|
Medium
|
9.6 |
Swipe to view all metrics
EYEARO® · NSR TECHNOLOGY™ · EST. BRAND 2025
YOUR EYES
POWER
EVERYTHING.
